Equity Overview
Price & Market Data
Price: $1.06
Daily Change: -$0.05 / 4.72%
Range: $1.04 - $1.14
Market Cap: $4,106,027
Volume: 47,820
Performance Metrics
1 Week: 22.97%
1 Month: 10.42%
3 Months: 15.41%
6 Months: -38.01%
1 Year: -64.67%
YTD: -6.16%
Company Details
Employees: 17
Sector: Health technology
Industry: Pharmaceuticals: major
Country: Canada
Details
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat gout and progressive kidney disease. Its drug development programs include XRx-026, which is in the third phase for the treatment of gout; XRx-008, which is in the second phase to treat autosomal dominant polycystic kidney disease; XRx-101, which is in the second phase to treat acute kidney injury associated with respiratory virus infection; and XRX-225, which is in the preclinical stage for the treatment of type 2 diabetic nephropathy. It has a license agreement with the University of Florida Research Foundation, Inc. for the use of uric acid lowering agent to treat insulin resistance. The company is based in Calgary, Canada.